ID: ALA4747319

Max Phase: Preclinical

Molecular Formula: C23H23N3O3

Molecular Weight: 389.46

Molecule Type: Unknown

Representations

Canonical SMILES:  Cn1c(Cc2cccc(C#N)c2)nc2cc(O[C@H]3CC[C@@H](C(=O)O)CC3)ccc21

Standard InChI:  InChI=1S/C23H23N3O3/c1-26-21-10-9-19(29-18-7-5-17(6-8-18)23(27)28)13-20(21)25-22(26)12-15-3-2-4-16(11-15)14-24/h2-4,9-11,13,17-18H,5-8,12H2,1H3,(H,27,28)/t17-,18+

Standard InChI Key:  OIJRKOUTKYMJRN-HDICACEKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 389.46

Molecular Weight (Monoisotopic): 389.1739

AlogP: 4.06

#Rotatable Bonds: 5

Polar Surface Area: 88.14

Molecular Species: ACID

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.20

CX Basic pKa: 5.96

CX LogP: 2.71

CX LogD: 1.38

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.71

Np Likeness Score: -1.03

References

1. Hayashi K,Kondo N,Omori N,Yoshimoto R,Hato M,Shigaki S,Nagasawa A,Ito M,Okuno T.  (2021)  Discovery of a benzimidazole series as the first highly potent and selective ACSL1 inhibitors.,  33  [PMID:33285268] [10.1016/j.bmcl.2020.127722]

Source

Source(1):

• Scientific Literature